March
F351 was granted a Breakthrough Therapy designation by the CDE.
May
We were awarded Beijing Municipal Specialized, Fine, Unique and Innovative “Small Giant” Enterprise by Beijing Municipal Bureau of Economy and Information Technology.
June
We were awarded Beijing Municipal “Specialized, Fine, Unique and Innovative” Small and Medium-Sized Enterprise by Beijing Municipal Bureau of Economy and Information Technology.
July
We received the NMPA's IND approval to conduct the Phase III clinical trial of F351 for the treatment of liver fibrosis associated with CHB.
F351 was granted a Breakthrough Therapy designation by the CDE.
May
We were awarded Beijing Municipal Specialized, Fine, Unique and Innovative “Small Giant” Enterprise by Beijing Municipal Bureau of Economy and Information Technology.
June
We were awarded Beijing Municipal “Specialized, Fine, Unique and Innovative” Small and Medium-Sized Enterprise by Beijing Municipal Bureau of Economy and Information Technology.
July
We received the NMPA's IND approval to conduct the Phase III clinical trial of F351 for the treatment of liver fibrosis associated with CHB.